HUP0003428A3 - Use of leptin antagonists for the treatment of diabetes - Google Patents
Use of leptin antagonists for the treatment of diabetesInfo
- Publication number
- HUP0003428A3 HUP0003428A3 HU0003428A HUP0003428A HUP0003428A3 HU P0003428 A3 HUP0003428 A3 HU P0003428A3 HU 0003428 A HU0003428 A HU 0003428A HU P0003428 A HUP0003428 A HU P0003428A HU P0003428 A3 HUP0003428 A3 HU P0003428A3
- Authority
- HU
- Hungary
- Prior art keywords
- diabetes
- treatment
- leptin antagonists
- leptin
- antagonists
- Prior art date
Links
- 102000016267 Leptin Human genes 0.000 title 1
- 108010092277 Leptin Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 title 1
- 229940039781 leptin Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP1997/002240 WO1998055139A1 (en) | 1997-06-06 | 1997-06-06 | Use of leptin antagonists for the treatment of diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0003428A2 HUP0003428A2 (hu) | 2001-05-28 |
| HUP0003428A3 true HUP0003428A3 (en) | 2001-12-28 |
Family
ID=8166613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0003428A HUP0003428A3 (en) | 1997-06-06 | 1997-06-06 | Use of leptin antagonists for the treatment of diabetes |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0986397A1 (hu) |
| JP (1) | JP2002504102A (hu) |
| KR (1) | KR20010013414A (hu) |
| AU (1) | AU2951797A (hu) |
| CA (1) | CA2293504A1 (hu) |
| HU (1) | HUP0003428A3 (hu) |
| IL (1) | IL133136A0 (hu) |
| TR (1) | TR199902980T2 (hu) |
| WO (1) | WO1998055139A1 (hu) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6777388B1 (en) | 1998-08-21 | 2004-08-17 | Clf Medical Technology Acceleration Program, Inc. | Leptin-related peptides |
| US7208572B2 (en) | 1998-08-21 | 2007-04-24 | Albany Medical College | Leptin-related peptides |
| US20050272652A1 (en) | 1999-03-29 | 2005-12-08 | Gault Victor A | Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity |
| EP2422807A3 (en) | 2004-02-11 | 2012-05-30 | Amylin Pharmaceuticals Inc. | Hybrid polypeptides with selectable properties |
| US8076288B2 (en) | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
| US8263545B2 (en) | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
| SG159551A1 (en) | 2005-02-11 | 2010-03-30 | Amylin Pharmaceuticals Inc | Gip analog and hybrid polypeptides with selectable properties |
| BRPI0614649A2 (pt) | 2005-08-11 | 2011-04-12 | Amylin Pharmaceuticals Inc | polipeptìdeos hìbridos com propriedades selecionáveis |
| AU2006279680B2 (en) | 2005-08-11 | 2012-12-06 | Amylin Pharmaceuticals, Llc | Hybrid polypeptides with selectable properties |
| US8497240B2 (en) | 2006-08-17 | 2013-07-30 | Amylin Pharmaceuticals, Llc | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
| WO2010118384A2 (en) | 2009-04-10 | 2010-10-14 | Amylin Pharmaceuticals, Inc. | Amylin agonist compounds for estrogen-deficient mammals |
| EP2621515B1 (en) | 2010-09-28 | 2017-03-29 | Aegerion Pharmaceuticals, Inc. | A chimeric seal-human leptin polypeptide with increased solubility |
| CN103957926B (zh) | 2011-07-08 | 2018-07-03 | 安米林药品有限责任公司 | 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽 |
| CN111529535A (zh) | 2012-09-27 | 2020-08-14 | 儿童医学中心公司 | 用于治疗肥胖症的化合物和其使用方法 |
| JP6672157B2 (ja) | 2013-11-26 | 2020-03-25 | ザ チルドレンズ メディカル センター コーポレーション | 肥満を処置するための化合物およびその使用方法 |
| US20170209408A1 (en) | 2014-04-03 | 2017-07-27 | The Children's Medical Center Corporation | Hsp90 inhibitors for the treatment of obesity and methods of use thereof |
| PT3509624T (pt) | 2016-09-12 | 2023-08-28 | Amryt Pharmaceuticals Inc | Métodos de deteção de anticorpos neutralizantes anti-leptina |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6309853B1 (en) * | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| AU695934B2 (en) * | 1995-06-30 | 1998-08-27 | Eli Lilly And Company | Methods for treating diabetes |
-
1997
- 1997-06-06 TR TR1999/02980T patent/TR199902980T2/xx unknown
- 1997-06-06 JP JP50135299A patent/JP2002504102A/ja active Pending
- 1997-06-06 KR KR19997011415A patent/KR20010013414A/ko not_active Application Discontinuation
- 1997-06-06 HU HU0003428A patent/HUP0003428A3/hu unknown
- 1997-06-06 IL IL13313697A patent/IL133136A0/xx unknown
- 1997-06-06 CA CA002293504A patent/CA2293504A1/en not_active Abandoned
- 1997-06-06 EP EP97923840A patent/EP0986397A1/en not_active Withdrawn
- 1997-06-06 WO PCT/EP1997/002240 patent/WO1998055139A1/en not_active Application Discontinuation
- 1997-06-06 AU AU29517/97A patent/AU2951797A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP0986397A1 (en) | 2000-03-22 |
| AU2951797A (en) | 1998-12-21 |
| KR20010013414A (ko) | 2001-02-26 |
| JP2002504102A (ja) | 2002-02-05 |
| WO1998055139A1 (en) | 1998-12-10 |
| HUP0003428A2 (hu) | 2001-05-28 |
| IL133136A0 (en) | 2001-03-19 |
| CA2293504A1 (en) | 1998-12-10 |
| TR199902980T2 (xx) | 2000-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL130027A (en) | Rosiglitazone - glyburide synergistic combinations for treatment of diabetes | |
| HUP0003428A3 (en) | Use of leptin antagonists for the treatment of diabetes | |
| HUP0002030A3 (en) | Use of glur5 receptorantagonists for the treatment of pain | |
| GB9824160D0 (en) | Heterocyclic compounds and their therapeutic use | |
| IL130831A0 (en) | Imino-aza-anthracylinone derivatives for the treatment of amyloidosis | |
| GB9810920D0 (en) | Therapeutic use | |
| GB9816897D0 (en) | Therapeutic use | |
| GB9812662D0 (en) | Therapeutic use | |
| PT1011678E (pt) | Utilização de mecamilamina para o tratamento de perturbações neuropsiquiátricas responsivas à nicotina. | |
| NO995940D0 (no) | Anvendelse av leptin antagonister for behandling av diabetes | |
| GB9821179D0 (en) | Therapeutic use | |
| GB9812664D0 (en) | Therapeutic use | |
| PL337220A1 (en) | Application of leptin antagonists in treating diabetes | |
| GB9819505D0 (en) | Heterocyclic compounds and their therapeutic use | |
| GB9820768D0 (en) | Heterocyclic compounds and their therapeutic use | |
| GB9714742D0 (en) | Medical cement | |
| GB9713240D0 (en) | Heterocyclic compounds and their therapeutic use | |
| GB9802622D0 (en) | Compounds and their therapeutic use | |
| GB9812314D0 (en) | Treatment of diabetes | |
| GB9815149D0 (en) | Treatment of diabetes | |
| GB9812666D0 (en) | Therapeutic use | |
| GB9812612D0 (en) | Therapeutic use | |
| GB9801581D0 (en) | Therapeutic use | |
| GB9812620D0 (en) | Therapeutic use | |
| GB9812615D0 (en) | Therapeutic use |